Anixa Biosciences (NASDAQ:ANIX) released its quarterly earnings results on Wednesday. The company reported ($0.08) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.02, Fidelity Earnings reports.
Shares of Anixa Biosciences stock opened at $4.33 on Friday. The company’s fifty day simple moving average is $4.32. The company has a market cap of $136.10 million, a PE ratio of -3.83 and a beta of 1.41. Anixa Biosciences has a 52 week low of $1.70 and a 52 week high of $8.09.
In related news, Director Emily Gottschalk acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, April 23rd. The stock was acquired at an average price of $4.49 per share, for a total transaction of $44,900.00. Over the last ninety days, insiders have purchased 30,000 shares of company stock valued at $137,150. 19.80% of the stock is owned by insiders.
About Anixa Biosciences
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus.
Read More: The basics of gap trading strategies
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.